The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.
 
Peter Schmid
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); Oncogenex (Inst)
 
Yeon Hee Park
No Relationships to Disclose
 
Eva Muñoz-Couselo
No Relationships to Disclose
 
Sung-Bae Kim
Research Funding - Dongkook (Inst); Kyowa Hakko Kirin (Inst); Novartis (Inst); Sanofi (Inst)
 
Joohyuk Sohn
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Hanmi; Novartis; Spectrum Pharmaceuticals
 
Esther Holgado
No Relationships to Disclose
 
Yang Wang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Thao Dang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Gursel Aktan
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck (I)
Travel, Accommodations, Expenses - Merck; Merck (I)
Other Relationship - Merck (I)
 
Javier Cortés
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Roche